Radioimmunotherapy directed to ccr8 for depletion of tumor infiltrating regulatory t cells

Abstract

Provided are methods for treating a solid cancer in a subject by administering an effective amount of a radioconjugated CCR8-targeting agent to deplete tumor-associated CCR8-positive Treg cells, alone or in combination with one or more additional therapeutic agents or modalities, such as a radioconjugated CD33-targeting agent.

Dependencies are inferred from the claim text.